• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Erectile Dysfunction - Pipeline Review, Q4 2010 - Product Image

Erectile Dysfunction - Pipeline Review, Q4 2010

  • ID: 1464213
  • December 2010
  • 59 pages
  • Global Markets Direct

Erectile Dysfunction - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Erectile Dysfunction Pipeline Review, Q4 2010”, provides an overview of the Erectile Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. “Erectile Dysfunction-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.
- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Erectile Dysfunction
Erectile Dysfunction Therapeutics under Development by Companies
Erectile Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Erectile Dysfunction Therapeutics Development
Eli Lilly and Company
Vectura Group plc
Chong Kun Dang Pharmaceutical
Dong-A Pharmaceutical Co., Ltd.
Pfizer Inc.
VIVUS, Inc.
Bayer AG
NovaDel Pharma, Inc.
Palatin Technologies, Inc.
Plethora Solutions Holdings plc
Rexahn Pharmaceuticals, Inc.
Fabre-Kramer Pharmaceuticals, Inc.
Quatrx Pharmaceutical Company
Ion Channel Innovations, LLC
Universities/Institutes Involved in Erectile Dysfunction Therapeutics Development
Erectile Dysfunction Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Alfuzosin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Androgel + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avanafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-8159 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Invicorp - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK3530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitaros - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Fluvastatin Sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Folic Acid + Tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Viagra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zydena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Erectile Dysfunction - Featured News
Dec 06, 2010: VIVUS Announces Positive Results From Long-Term Phase III Study Of Avanafil In Erectile Dysfunction
Nov 15, 2010: Apricus Biosciences Receives Canadian Approval For Vitaros As First Line Therapy For Erectile Dysfunction
Oct 15, 2010: NovaDel Reports Positive Data From Pilot Pharmacokinetic Study Comparing Duromist To Viagra Tablet
Sep 02, 2010: Palatin Technologies Completes First Cohort Dosing Study Of Bremelanotide For The Treatment Of Sexual Dysfunction
Aug 17, 2010: Palatin Announces Positive Safety Results From Phase I Subcutaneous Bremelanotide Trial In Men
Jun 24, 2010: Nexmed Receives First Patent For Vitaros In Japan
Jun 23, 2010: NexMed Receives Screening Acceptance Letter From Health Canada For Vitaros
Jun 10, 2010: Nexmed Provides Update On Canadian Filing For Vitaros
Jun 07, 2010: VIVUS Announces Positive Results From Phase III Study Of Avanafil In Diabetics With Erectile Dysfunction
Jun 01, 2010: VIVUS Announces Positive Results From Phase III Study Of Avanafil In Erectile Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos